bmy88 com login register
bmy88 com login register
NewtekOne, Inc. ( NASDAQ:NEWT – Get Free Report ) announced a quarterly dividend on Friday, December 13th, Wall Street Journal reports. Investors of record on Tuesday, December 31st will be given a dividend of 0.19 per share by the business services provider on Monday, January 13th. This represents a $0.76 annualized dividend and a yield of 5.84%. The ex-dividend date is Tuesday, December 31st. NewtekOne has decreased its dividend by an average of 29.5% annually over the last three years. NewtekOne has a payout ratio of 35.7% meaning its dividend is sufficiently covered by earnings. Equities research analysts expect NewtekOne to earn $2.12 per share next year, which means the company should continue to be able to cover its $0.76 annual dividend with an expected future payout ratio of 35.8%. NewtekOne Stock Performance Shares of NEWT stock opened at $13.01 on Friday. The company has a market cap of $342.23 million, a P/E ratio of 7.27 and a beta of 1.30. The business has a 50 day moving average of $13.80 and a two-hundred day moving average of $13.08. NewtekOne has a 52 week low of $10.07 and a 52 week high of $15.49. The company has a quick ratio of 0.75, a current ratio of 0.75 and a debt-to-equity ratio of 4.98. Analyst Upgrades and Downgrades NEWT has been the topic of a number of analyst reports. B. Riley increased their price objective on shares of NewtekOne from $13.00 to $14.00 and gave the stock a “neutral” rating in a report on Thursday, December 19th. Piper Sandler raised their price target on shares of NewtekOne from $13.00 to $15.00 and gave the company a “neutral” rating in a research note on Monday, November 11th. Finally, Keefe, Bruyette & Woods reiterated a “market perform” rating and set a $15.00 price objective (up from $13.00) on shares of NewtekOne in a research report on Friday, November 8th. View Our Latest Stock Report on NewtekOne Insider Buying and Selling In related news, CEO Barry Sloane acquired 3,000 shares of the stock in a transaction that occurred on Monday, December 23rd. The shares were acquired at an average price of $12.95 per share, for a total transaction of $38,850.00. Following the completion of the purchase, the chief executive officer now directly owns 1,164,855 shares of the company’s stock, valued at $15,084,872.25. The trade was a 0.26 % increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is available through the SEC website . Insiders purchased 8,750 shares of company stock valued at $119,568 over the last 90 days. 6.50% of the stock is currently owned by company insiders. About NewtekOne ( Get Free Report ) NewtekOne, Inc operates as the bank holding company for Newtek Bank, National Association that engages in the provision of various business and financial solutions under the Newtek brand name to the small- and medium-sized business market. The company accepts demand, savings, NOW, money market, and time deposits; and provides loans including SBA loans, commercial and industrial loans, and commercial real estate loans. Recommended Stories Receive News & Ratings for NewtekOne Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NewtekOne and related companies with MarketBeat.com's FREE daily email newsletter .Walmart’s DEI rollback signals a profound shift in the wake of Trump’s election victoryTo buy or not to buy airline stocks in 2025? It's a good question because, at the time of writing, shares in premier airlines United Airlines ( UAL -1.21% ) and Delta Air Lines ( DAL -1.83% ) were up by 145% and 55%, respectively, in 2024. Such remarkable performances are seldom repeated the following year, yet United trades at 8.1 times earnings estimates for 2025, and Delta at 8.4 times. Let's look closer at United and what investors might expect from the airline in 2025. Why United Airlines outperformed in 2024 The share price charts of United and Delta might surprise investors. They tracked each other until the summer, but United outperformed from then onward. Understanding the reasons helps shed light on the current operational momentum behind the stock. There are two reasons for their stock performance. First, United was relatively less impacted than Delta by the CrowdStrike software update issue, which caused significant flight disruptions in the summer. Second, and arguably much more importantly from a long-term perspective, United benefited more from the airline industry 's rational decision to remove unprofitable capacity in the summer. It's a point acknowledged by United CEO Scott Kirby on the last earnings call when he noted that "United's domestic capacity in 2024 was shaped with the expectation that the industry would remove unprofitable capacity in earnest in Q4." Kirby explained that this conscious decision meant United "expanded slower than most during the first three quarters of the year when capacity dynamics were less favorable." Still, industry conditions are now favorable as both United and Delta management have confirmed that excess capacity was taken out of the market during the summer. As such, United's stock outperformed as it had more upside exposure to the airline industry, the company having acted more disciplined. If this behavior continues, investors have reason to believe that the airline industry's periodic boom-and-bust cycles might not be as frequent or dramatic as in the past. DAL data by YCharts A structural shift in 2025 Building on the last point, it's fair to say that airline stocks are priced as if a bust could be imminent. The table below uses the Wall Street analyst consensus estimates, which say the stock is cheap. However, the estimates don't tell you how concerned investors are that United and the others might not meet these expectations. Airline P/E 2024 (est) EPS Growth in 2025 (est) P/E 2025 (est) United Airlines 9.6 20.4% 8.1 Delta Air Lines 10.3 22.6% 8.4 American Airlines 10.4 36.9% 7.6 Data source: Wall Street estimates. Analysis by author.. That said, three factors point to United having an excellent 2025 and confirm Kirby's assertion that United has excellent momentum going into the year. First, management sees the higher-margin corporate traveler returning, and United's chief commercial officer Andrew Nocella sees corporate growth accelerating in the first quarter. Similarly, 85% of respondents to a Delta corporate survey said they expect increased spending on travel in 2025. Second, the two most widely followed airline industry metrics, revenue per available seat mile (RASM) and cost per available seat mile excluding fuel (CASM-ex) are moving in the right direction. While total RASM was down 1.6% in the third quarter year over year, management outlined that it passed an inflection point in the quarter. The momentum improving in the third quarter will likely build into the fourth quarter of 2024, and the pricing environment is improving. Meanwhile, United's CASM-ex will "decline into the fourth quarter and to decline further into 2025," according to CFO Michael Leskinen. Finally, the industry dynamics of more disciplined behavior (discussed above) and the financial and competitive pressures on low-cost carriers (United has been particularly successful in its basic economy offering) like Spirit Airlines mean the pricing and competitive environment are improving for United Airlines. A stock to buy for 2025 Everything points to United having another strong operational year in 2025, which will likely be reflected in its share price performance. If the economy behaves and consumer spending is supported by growing corporate spending, then United Airlines is positioned to have another great year.
SOPHIA, the world’s most advanced humanoid robot, has arrived at the University of Zimbabwe Diamond Centre, captivating an audience eager to glimpse at the future of artificial intelligence (AI). Known for her ability to engage in human-like conversations, Sophia is no stranger to Africa, having visited several countries on the continent, each with unique outcomes. Her stop in Zimbabwe is significant — it signals the country’s intent to position itself in the global tech landscape. But Sophia’s visit is more than a technological showcase; it challenges us to reflect on what AI means for Africa and the philosophies that underpin our relationship with machines. Sophia’s previous visits to Africa have left an indelible mark. In 2018, she toured Ethiopia, where she met government officials and technology students at the Artificial Intelligence Institute in Addis Ababa. There, she sparked conversations about Ethiopia’s tech sector and the country’s ambition to become a hub for AI innovation in Africa. She also visited Egypt, where she participated in the World Youth Forum, engaging in discussions about youth empowerment, technology and sustainable development. In each country, Sophia’s presence did more than draw crowds — it inspired actionable steps. Ethiopia launched AI-driven initiatives to improve agriculture and healthcare, while Egypt explored integrating AI into government services. Her visits highlight the importance of not merely marvelling at advanced technology but adopting it to address local challenges. The question now is whether Zimbabwe can follow this pattern and turn Sophia’s visit into a catalyst for change and progress. The choice of the University of Zimbabwe Diamond Centre as the venue for Sophia’s unveiling is symbolic. Zimbabwe’s diamond industry is a cornerstone of its economy but often criticised for limited local beneficiation and over-reliance on raw exports. Sophia’s presence invites us to imagine a different future — one where AI and robotics add value to natural resources, increasing transparency, efficiency and sustainability in industries like mining. Sophia herself embodies the potential of AI to enhance human capabilities. Could Zimbabwean innovators create AI systems tailored for local needs, such as robots that improve farming practices or AI-driven tools for urban planning? The opportunity is vast, but it requires more than ambition; it demands investment in education, infrastructure and innovation ecosystems. Sophia’s visit also raises key philosophical questions about our relationship with machines. The French philosopher René Descartes famously declared: “Cogito, ergo sum” (“I think, therefore I am”), distinguishing human beings from machines based on the ability to think. Sophia blurs this line. While she does not “think” in the human sense, her ability to mimic human conversation challenges our understanding of consciousness and intelligence. Sophia’s existence also brings to mind Aristotle’s concept of telos, or purpose. Aristotle believed everything in nature has a purpose that defines its essence. What, then, is the telos of robots like Sophia? Are they mere tools to serve humanity, or do they have a purpose beyond our utility? For Africa, these questions are not academic. As we integrate AI into our societies, we must decide how these technologies fit into our values and priorities. Will they deepen inequalities or empower communities? Will they replace human labour or augment it? The answers depend on the choices we make today. In a country like Zimbabwe, Sophia’s visit inevitably sparks concerns about the future of work. The answer lies in understanding AI as a tool for complementing, not replacing, human effort. Sophia could inspire innovations in health care, where AI-driven tools might support overstretched medical staff, or in education, where AI tutors could bridge gaps in rural schools. These technologies would not take jobs but create new roles requiring skills in programming, maintenance and AI ethics. However, these opportunities come with challenges. Africa must tackle issues of data privacy, algorithmic bias and the digital divide. If AI systems are designed elsewhere and imported wholesale, they risk perpetuating inequalities. Local development of AI systems, informed by African contexts and values, is critical. Sophia’s unveiling in Zimbabwe should not end as a fleeting spectacle. The enthusiasm it generates must translate into tangible actions. The Government, the private sector and academic institutions must collaborate to create an environment where innovation thrives. Countries like Ethiopia have shown that Sophia’s visit can be more than symbolic. Zimbabwe can draw lessons from these examples by investing in AI research and development, creating policies that foster tech start-ups and ensuring that technology serves the broader population. At the same time, Sophia’s visit is a moment for self-reflection. Zimbabwe and Africa as a whole must define their philosophy of technology. Are we content with being consumers of innovation, or do we aim to be creators? Are we building technologies that reflect our unique challenges and strengths, or are we importing solutions that may not fit our needs? Sophia’s visit to Zimbabwe is a reminder that the future is not something that happens to us; it is something we actively shape. Africa’s youthful population, abundant resources and growing tech hubs give it a unique advantage in the global AI race. But realising this potential requires moving from inspiration to action. Let us ensure that this moment is not just about celebrating Sophia but about empowering the next generation of Zimbabwean and African innovators. Sophia is a marvel of engineering, but the real marvel will be the day Zimbabwe unveils its own Sophia — a robot born of African ingenuity, solving African problems and embodying African values. The future is here. It is time for Africa to lead it.
Abacus Life Completes Acquisition of FCF Advisors
I Let AI and My 5-Year-Old Pick My Stocks. Who Did Better?Man City Blow Three-goal Lead In Champions League, Bayern Beat PSG
NASHVILLE, Tenn. — The Iowa football team will be without a few key contributors when it faces No. 19 Missouri in the Music City Bowl on Monday. According to head coach Kirk Ferentz, starting center Logan Jones, wide receiver Seth Anderson and defensive back Koen Entringer will be out for the Hawkeyes (8-4, 6-3 Big Ten) in their matchup against the Tigers (9-3, 5-3 Southeastern) due to injury. Iowa center Logan Jones (65) prepares to snap the ball against Michigan State on Sept. 30. CHARLIE NEIBERGALL, ASSOCIATED PRESS Senior offensive lineman Tyler Elsbury will start at center in the place of Jones. “Last year, Tyler stood in there for four games when Logan missed,” Ferentz said. “Els did a great job, really good job. That is a real benefit. It is a luxury item, quite frankly, to have him available. “It is hard to replace a guy like Logan. Logan is not only a really good football player, team leader, he will be on the sideline tomorrow and cannot go, unfortunately. Tyler will do a good job. Great opportunity for him. I know he is excited about it.” Senior linebacker Kyler Fisher will also miss the bowl game due to an “unmet eligibility requirement.” “He is not going to be able to compete,” Ferentz said. “He has been with us. ... He missed something, an assignment, whatever it may have been. He has chosen to stay with the team. He is a senior and practiced each and every day, been on the look squad. That was not beneath him. He has been doing a great job working against our defense.” Ferentz added the team became aware of the issue with Fisher’s eligibility a few weeks ago. “He made every effort to make it to the finish line, but just was not able to,” Ferentz said. “It is unfortunate. ... It is a tough break. Nothing malicious, anything like that. He is the one that is hurting more than anybody, but we will be fine. “It is unfortunate that he won’t play, but he has been here doing a great job and he will be on the sidelines with us tomorrow.” Iowa head coach Kirk Ferentz celebrates with quarterback Brendan Sullivan (1) during the first half against Wisconsin Nov. 2 in Iowa City. CHARLIE NEIBERGALL, ASSOCIATED PRESS During his press conference on Sunday, Missouri head coach Eli Drinkwitz praised the Iowa program and its head coach. “Our football team is excited,” Drinkwitz said. “One of the things you look forward to is obviously the host city, but also the competition that you get to play against and the opportunity to play against a traditional powerhouse in Iowa. I have a tremendous amount of respect for Kirk Ferentz and what he has done with the Hawkeye football team over the course of his 26-year career. “He is the gold standard of college football and what it takes to build and sustain a program of success and excellence, player development. So it's a real honor to be on the same football field with him and his program.” Drinkwitz followed up his praise for the Hawkeyes with his expectations for his team and their performance. “We are going to have to play a clean football game,” Drinkwitz said. “You watch these bowl games. It's going to come down to turnovers and takeaways, tackling, and penalties. We've got to be clean in those areas to give ourselves a chance. One of the hallmarks of Coach Ferentz' football teams is they just don't beat themselves. They force the other team into mistakes, and we're going to have to do a nice job of playing sound football.” Specifically in regards to Iowa’s defense, the fifth-year head coach added he sees no weak links on the formidable unit. “It is a real challenge,” Drinkwitz said. “You have to beat the whole team. You can't just beat one person. You can't just beat one matchup. You have to beat the whole team in order to have a chance to win.” FILE - Missouri head coach Eliah Drinkwitz watches his team during an NCAA college football intra-squad spring game Saturday, March 19, 2022, in Columbia, Mo. Missouri coach Eli Drinkwitz welcomed 19 transfers among 50 newcomers to the Tigers this season, and 14 of them arrived from Division I schools. (AP Photo/Jeff Roberson, File) Jeff Roberson During his press conference, Drinkwitz also made a point to highlight one similarity between Missouri and Iowa, which he said he shared with Ferentz earlier in the week. “Our two programs have done a really good job,” Drinkwitz said. “We have only had two opt-outs on both sides because of potential NFL futures, and careers and we totally understand that, but the rest of the senior classes are wanting to play and they want to play together for the brotherhood. “We have a lot of seniors that this is going to be their final football game for the Missouri Tigers and what a wonderful legacy that they leave to have an opportunity to finish out their careers the right way. ... All of those guys hold a special place in Mizzou football history.” Speaking specifically on his program, Ferentz attributed the low number of opt-outs to the Hawkeyes playing for “the right reason.” “The good of the game is just a chance to be together and go out and compete together and go through the work leading up to the competition,” Ferentz said. “...If you do not like that part in football, you are probably in the wrong sport. “That is kid of the nature of football and the nature of being part of a team. ... That is what you miss when you are done playing. We have been very fortunate. We have had a lot of really good young guys in this program — a bunch of them on this team too.” According to Iowa offensive coordinator Tim Lester, the senior class provided valuable leadership in his first year with the program. “They have meant a lot to this program, meant a lot to me especially coming in and putting a lot of new stuff in,” Lester said. “I am excited for them and excited for their opportunity tomorrow.” Ferentz offered his thoughts on the Tigers after praising Drinkwitz two weeks ago. “They have got an outstanding football team,” Ferentz said. “... You look at them on film. They are really good offensively — very balanced. They have two outstanding running backs, guys we have a lot of respect for (and) a good offensive line. “They have a good receiver corps. ... The whole key to their offense is a quarterback. He has done a wonderful job with his career. Really good football player. To me, he is the catalyst for their offensive football team.” Missouri senior quarterback Brady Cook completed 63.3% of his passes for 2,248 yards and nine touchdowns to two interceptions in 2024. The St. Louis native added 169 yards and five touchdowns on the ground. Defensively, Ferentz said Missouri presents as a typical challenge out of the Southeastern Conference. “They are big and physical up front,” Ferentz said. Ferentz concluded his thoughts on the Tigers saying they check all the boxes in terms of ball security, penalties and time of possession. “They do a great job which indicates they are very well-coached,” Ferentz said. “They pay attention to things that are important and know what to do there.” Brendan Sullivan remains consistent amid Iowa’s search for quarterback in portal Veteran college football coach expects former boss Bill Belichick to turn North Carolina around Iowa’s backfield in good hands against Missouri despite Kaleb Johnson’s exit SEC Bias? What bowl matchup against Missouri means to IowaJimmy Carter, the former U.S. president renowned for his role in the Camp David Accords, passed away peacefully at his home in Plains, Georgia, at age 100. Despite facing economic challenges and the Iran hostage crisis during his presidency, Carter's post-White House life was marked by significant humanitarian contributions that earned him a Nobel Peace Prize in 2002. Carter, whose moral fortitude and commitment to peace were hallmarks of his tenure, was honored by U.S. President Joe Biden, who declared January 9 a national day of mourning. Carter's legacy includes diplomatic successes in the Middle East and efforts to advance human rights and democracy worldwide. His contributions extended to election monitoring and crisis resolution in hotspots like Bosnia and Haiti. While Carter's presidency faced domestic hurdles, including inflation and interest rates, his diplomatic efforts left a lasting impact. He has been remembered as a principled leader who brought significant change through peaceful means. As the world reflects on his accomplishments, Carter's profound influence remains a testament to his belief in justice and equality. (With inputs from agencies.)
Lumina Gold Announces US$6.0 Million Wheaton Precious DrawSimon Webb and Duncan Nicholls Over the past week, I’ve been planning a bold move on Micron Technology, Inc. ( NASDAQ: MU ), and today, Friday, December 13th, I finally pulled the trigger. It's a two-step play: first, I'm shorting the company with deep Analyst’s Disclosure: I/we have a beneficial short position in the shares of MU either through stock ownership, options, or other derivatives. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article. Seeking Alpha's Disclosure: Past performance is no guarantee of future results. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. Any views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker or US investment adviser or investment bank. Our analysts are third party authors that include both professional investors and individual investors who may not be licensed or certified by any institute or regulatory body.BOSTON (AP) — Two men, including a dual Iranian American citizen, have been arrested on charges that they exported sensitive technology to Iran that was used in a drone attack in Jordan that killed three American troops early this year and injured dozens of other service members, the Justice Department said Monday. The pair were arrested after FBI specialists who analyzed the drone traced the navigation system to an Iranian company operated by one of the defendants, who relied on technology funneled from the U.S. by his alleged co-conspirator, officials said. Javascript is required for you to be able to read premium content. Please enable it in your browser settings.
Nick Saban Suggested as 'Obvious Choice' for Possible College Football CommissionerAidan O'Connell threw two touchdown passes, Daniel Carlson kicked four field goals, Ameer Abdullah had the first 100-yard rushing game of his career and the visiting Las Vegas Raiders defeated the New Orleans Saints 25-10 on Sunday afternoon. Abdullah, playing in the 141st game of his 10-year career, finished with 115 yards on 20 carries. O'Connell completed 20 of 35 passes for 242 yards as the Raiders (4-12) won their second straight after a 10-game losing streak. Brock Bowers added seven receptions for 77 yards, giving him 1,144 receiving yards, which broke the NFL single-season record for a rookie tight end, set by Mike Ditka with 1,076 yards in 14 games in 1961. Rookie Spencer Rattler passed for 218 yards with a touchdown and two interceptions and fell to 0-5 as the starter for the Saints (5-11). Las Vegas's first possession of the third quarter resulted in Carlson's 54-yard field goal, which increased its lead to 16-10 at the end of the period. Carlson's 25-yard field goal pushed the lead to 19-10 on the third play of the fourth quarter. O'Connell added an 18-yard touchdown pass to Tre Tucker to complete the scoring. The Raiders received the opening kickoff and held the ball for 17 plays before stalling. Carlson kicked a 31-yard field goal and the 3-0 lead held up through the end of the first quarter. On the first play of the second quarter, Rattler threw a 30-yard touchdown pass to former Raiders tight end Foster Moreau and the Saints took a 7-3 lead with their first points in the first half in three games. The ensuing possession ended with Carlson kicking a 39-yard field goal that trimmed the lead to 7-6. O'Connell threw a 3-yard touchdown pass to Jakobi Meyers to give Las Vegas a 13-7 lead with 57 seconds left in the second quarter. Rattler completed 5 of 7 for 54 yards in driving New Orleans to Blake Grupe's 34-yard field goal as time expired that trimmed the lead to 13-10 at halftime. --Field Level MediaFamily-Friendly Perks and Huge Discounts Highlight Princess Cruises' 'Come Aboard Sale on 2025 - 2027 Sailings
TV star Charlotte Crosby said she has tightened security around her home with 24-hour monitored CCTV and patrol dogs, days after masked thieves carrying a machete attempted to rob her home. The former Geordie Shore star, who is nearly eight months pregnant, thanked a security company “for all the hard work this week” after adding the protections to her home. “Trebling our security measures, worth every penny to feel safe again in my own home,” the 34-year-old said in a post to her Instagram story. “Scumbags are gunna get a big shock the next time they even step foot on any perimeter of my land.” It comes after her fiance, Jake Ankers, said on social media that a group of men carrying a machete entered their home on Thursday evening while they were in the house with their two-year-old daughter. The businessman said one of the four men “had a red balaclava on” and was carrying the weapon at the top of the stairs. Durham Constabulary were alerted at 7pm on Thursday to reports of an aggravated burglary in Houghton-le-Spring, a town in the Sunderland area. A spokeswoman for the force said: “Officers attended the area, however the suspects left the scene before their arrival. “Nobody was injured in the incident and no items are believed to have been taken.” She added that an investigation is under way and anyone with information is asked to contact police. After the incident, Crosby was admitted to hospital after experiencing “serious pains” in her stomach, but confirmed her baby is “all fine”. Ankers appeared with the reality star on BBC Three reality show Charlotte In Sunderland. Crosby is best known for appearing in the MTV reality series Geordie Shore and winning the 12th series of Celebrity Big Brother in 2013. She and Ankers got engaged in October 2023 after she gave birth to their first child in 2022.
SOUTH SAN FRANCISCO, Calif., Dec. 02, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. VXRT today announced completion of enrollment of the sentinel cohort of a Phase 2b clinical trial evaluating Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA vaccine comparator. The sentinel cohort comprised of 400 participants, with 200 receiving Vaxart's COVID-19 vaccine candidate and 200 receiving an approved mRNA vaccine comparator. "We are pleased to complete the enrollment of the sentinel cohort, an important milestone that reflects the collaboration of our entire team, as well as the trust and commitment of the participants and investigators involved," said Dr. James F. Cummings, Vaxart's Chief Medical Officer. "We look forward to DSMB and FDA review followed by the planned initiation of the Phase 2b trial's second portion. Our continued progress brings us closer to our goal of potentially demonstrating advantages of our mucosal technology against an approved mRNA vaccine." An independent Data and Safety Monitoring Board (DSMB) and the U.S. Food and Drug Administration (FDA) will review 30-day safety data from the sentinel cohort. Upon favorable review by the DSMB and FDA, the study will progress after Biomedical Advanced Research and Development Authority (BARDA) approval to the second part of the trial by enrolling approximately 10,000 participants. The trial will strive to enroll participants in line with U.S. demographics, as well as including at least 25% over the age of 65. The Phase 2b trial is a double-blind, multi-center, randomized, comparator-controlled study to determine the relative efficacy, safety, and immunogenicity of Vaxart's oral pill COVID-19 vaccine candidate against an approved mRNA COVID-19 injectable vaccine in adults previously immunized against COVID-19 infection. The full Phase 2b trial will measure efficacy for symptomatic and asymptomatic disease, systemic and mucosal immune induction, and the incidence of adverse events. The primary endpoint is relative efficacy of Vaxart's COVID-19 vaccine candidate compared to an approved mRNA comparator for the prevention of symptomatic disease. Primary efficacy analysis will be performed when all participants have either discontinued or completed a study visit 12 months post-vaccination. Funding for this award was received under Project NextGen, a $5 billion initiative led by BARDA and the National Institute of Allergy and Infectious Diseases (NIAID) to accelerate and streamline the development of the next generation of innovative COVID-19 vaccines, therapeutics, and enablers. Vaxart's project award through the Rapid Response Partnership Vehicle (RRPV) is valued at up to $456 million. This project has been funded with federal funds from the U.S. Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); BARDA, under Other Transaction (OT) number 75A50123D00005. As a pioneer of oral vaccines, Vaxart was the first U.S. company to complete a Phase 2 clinical trial of an oral vaccine for COVID-19. About Vaxart Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart's development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart's first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists. Note Regarding Forward-Looking Statements This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, results from preclinical and clinical trials and the timing of such results, commercialization agreements and licenses, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "should," "believe," "could," "potential," "will," "expected," "anticipate," "plan," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart's ability to develop and commercialize its product candidates, including its vaccine booster products; Vaxart's expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; and Vaxart's expectations with respect to the effectiveness of its product candidates. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, regulatory submission dates, regulatory approval dates, and/or launch dates, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that, even if approved by the FDA or non-U.S. regulatory authorities, Vaxart's product candidates may not achieve broad market acceptance; that a Vaxart collaborator may not attain development and commercial milestones; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart's or its partners' control; difficulties in production, particularly in scaling up initial production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel or key raw materials, and compliance with strictly enforced federal, state, and foreign regulations; that Vaxart may not be able to obtain, maintain, and enforce necessary patent and other intellectual property protection; that Vaxart's capital resources may be inadequate; Vaxart's ability to resolve pending legal matters; Vaxart's ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the "Risk Factors" sections of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law. Contact Vaxart Media and Investor Relations : Matt Steinberg FINN Partners IR@vaxart.com (646) 871-8481 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.Nestled along two converging rivers, with the Blue Ridge Mountains’ precipitous cliffs offering a backdrop, Harpers Ferry has long been praised for its rugged natural beauty. The town named for millwright Robert Harper in 1747 soon became one of Thomas Jefferson’s favorite retreats, and today, the mound of Harpers shale on which he stood to survey the water gap below is a popular destination along the Appalachian Trail. George Washington chose Harpers Ferry for a new national armory in 1796. It turned what had been a somewhat sleepy hamlet into a prosperous industrial village. Yet this easternmost town in West Virginia didn’t gain national fame until the Civil War. It was here, in 1859, that abolitionist John Brown and his small group of men seized the armory in hopes of starting an uprising in the South against slavery. If you love history, it lives on at Harpers Ferry, which became a national historic park in 1963. It focuses not just on John Brown’s raid and the Civil War but also shines a light on African American history, industry, transportation and natural heritage. And if you find joy in hiking, cycling, mountaineering or paddling, you will find lots to do in and around this picturesque town on the Shenandoah and Potomac rivers. There also are numerous shops and restaurants, including in nearby Bolivar, if eating, drinking and shopping are high on your to-do list. Walking around charming Lower Town gives the feeling of stepping back in time. One of the most visited historic sites is the only armory building to escape destruction during the Civil War: John Brown’s Fort, where the abolitionist and several followers barricaded themselves during the final hours of their doomed raid. In 1891, it was dismantled and transported to Chicago for the World’s Fair. Other buildings reach even further into the past. When Harper established a ferry across the Potomac River in 1761, it made the town a starting point for settlers moving into the Shenandoah Valley and farther west. They included members of the famed Lewis and Clark expedition, who in 1803 made preparations here for their historic exploration of the western portion of the country after the Louisiana Purchase. Harpers Ferry became a ghost town by the 1950s and was reconstructed by the Park Service in the ’60s as a “multileveled interpretive proving ground.” Wearing comfortable shoes? National Park Service rangers lead free tours detailing the history of Harpers Ferry National Historical Park. Or take a self-guided Black heritage walking tour that includes 34 stops. Lower Town also includes an industry museum, a 19th-century “landscape” that will fascinate the kids, and both Civil War and Black history museums. And if you climb the rocky set of 44 steps that were carved into the hillside in 1810 behind the museums, you can take in a view of the city below from the stone patio of St. Peter’s Roman Catholic Church. West Virginia is famous for its variety of outdoor activities on both land and water, and Harpers Ferry does not disappoint. The Appalachian Trail, one of America’s most famous footpaths, passes through Lower Town, and visitors can trek or bike the Chesapeake and Ohio Canal towpath that runs along the banks of the Potomac River. (You’ll find maps at the Visitors Center.) If you don’t mind breaking a sweat and have a few hours, a moderately strenuous but rewarding hike follows the Maryland Heights trailhead to Overlook Cliff. The climb is both steep (1,154 feet uphill) and long (a 4.5-mile loop). But when you get to the top, the view of Harpers Ferry below is bucket- list spectacular. Less challenging (but not accessible to those with physical limitations) is the hike up the Stone Steps to St. Peter’s church, past the ruins of St. John’s Episcopal Church, to Jefferson Rock. You’re not allowed to climb onto the Harpers shale slab that gave Jefferson such pleasure, but you’ll share his terrific view. Continue up the hill a little farther, and you’ll hit the Appalachian Trail on your way to Camp Hill, the 32-acre site that once housed Storer College and is now owned by the Park Service. Harpers Ferry is considered the halfway point of the trail, and during the season, weary-looking hikers are a common sight around town and on the towpath across the Potomac. Many stop at the trail’s hikers’ lounge on Washington Street to rest or take a picture on its front porch. So far in 2024, visitor-center rep Dave Tarasevich has counted more than 1,240 northbound hikers. “It’s one of the few places where the trail goes through town, literally,” he said. Water sports, including fishing, are also popular here. Some people canoe and kayak through October; there’s also white water rafting in season. You also can go horseback riding. After all that walking and history learning, you’re going to want to unwind with some good food and drink. While you won’t find big-city gourmet eats, you can get a pretty good meal at several places around town. I had a tasty salad made with microfarm hemp hearts, greens, tomatoes and avocado on the patio at The Rabbit Hole and a pretty good burger at Coach House Bar and Grill. For coffee, fresh-baked pastries and sandwiches, head to Battle Grounds Bakery & Coffee. If you don’t eat meat, West Virginia’s very first vegan restaurant — Kelley Farm Kitchen in Bolivar — has got you covered with salads, Impossible burgers, hoagies and ramen bowls. Some places are dog-friendly, including my favorite spot for pizza and a beer — Harpers Ferry Brewing in neighboring Purcellville, Virginia. Perched on the side of a mountain next to Harpers Ferry Adventure Center, it offers an awesome view along with local craft brews and live music on weekends through November. Just know that everything in this small town, even the brewery, shutters pretty early. The only life downtown after dark is The Barn of Harpers Ferry, a music venue and bar that offers live music every night Wednesday through Saturday. Want to take a piece of West Virginia home with you? In boutiques along High Street and Public Way, you’ll find everything from original art and distinctive jewelry crafted by regional hands to old-fashioned candy and confections, antiques and hokey souvenirs. Lodging options include bed and breakfasts, campgrounds, a hostel and locally and nationally owned motels. For a guide on where to eat, seasonal events and other attractions, visit wherealmostheavenbegins.com .Raiders find winning formula again in topping SaintsTHOUSAND OAKS, Calif. , Dec. 2, 2024 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will present at Citi's 2024 Global Healthcare Conference at 9:30 a.m. ET on Thursday , Dec. 5, 2024. Peter Griffith , executive vice president and chief financial officer at Amgen, Jay Bradner , executive vice president of Research and Development and chief scientific officer at Amgen, and Susan Sweeney , executive vice president of Obesity and Related Conditions at Amgen, will participate in a fireside chat at the conference. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public. The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com , under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. About Amgen Amgen discovers, develops, manufactures and delivers innovative medicines to help millions of patients in their fight against some of the world's toughest diseases. More than 40 years ago, Amgen helped to establish the biotechnology industry and remains on the cutting-edge of innovation, using technology and human genetic data to push beyond what's known today. Amgen is advancing a broad and deep pipeline that builds on its existing portfolio of medicines to treat cancer, heart disease, osteoporosis, inflammatory diseases and rare diseases. In 2024, Amgen was named one of the "World's Most Innovative Companies" by Fast Company and one of "America's Best Large Employers" by Forbes, among other external recognitions . Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average ® , and it is also part of the Nasdaq-100 Index ® , which includes the largest and most innovative non-financial companies listed on the Nasdaq Stock Market based on market capitalization. Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2023, Amgen was named one of "America's Greatest Workplaces" by Newsweek, one of "America's Climate Leaders" by USA Today and one of the "World's Best Companies" by TIME. For more information, visit Amgen.com and follow us on X (formerly known as Twitter), LinkedIn , Instagram , TikTok , YouTube and Threads . Amgen Forward-Looking Statements This news release contains forward-looking statements that are based on the current expectations and beliefs of Amgen. All statements, other than statements of historical fact, are statements that could be deemed forward-looking statements, including any statements on the outcome, benefits and synergies of collaborations, or potential collaborations, with any other company (including BeiGene, Ltd. or Kyowa Kirin Co., Ltd.), the performance of Otezla ® (apremilast) (including anticipated Otezla sales growth and the timing of non-GAAP EPS accretion), our acquisitions of Teneobio, Inc., ChemoCentryx, Inc., or Horizon Therapeutics plc (including the prospective performance and outlook of Horizon's business, performance and opportunities, any potential strategic benefits, synergies or opportunities expected as a result of such acquisition, and any projected impacts from the Horizon acquisition on our acquisition-related expenses going forward), as well as estimates of revenues, operating margins, capital expenditures, cash, other financial metrics, expected legal, arbitration, political, regulatory or clinical results or practices, customer and prescriber patterns or practices, reimbursement activities and outcomes, effects of pandemics or other widespread health problems on our business, outcomes, progress, and other such estimates and results. Forward-looking statements involve significant risks and uncertainties, including those discussed below and more fully described in the Securities and Exchange Commission reports filed by Amgen, including our most recent annual report on Form 10-K and any subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Unless otherwise noted, Amgen is providing this information as of the date of this news release and does not undertake any obligation to update any forward-looking statements contained in this document as a result of new information, future events or otherwise. No forward-looking statement can be guaranteed and actual results may differ materially from those we project. Our results may be affected by our ability to successfully market both new and existing products domestically and internationally, clinical and regulatory developments involving current and future products, sales growth of recently launched products, competition from other products including biosimilars, difficulties or delays in manufacturing our products and global economic conditions. In addition, sales of our products are affected by pricing pressure, political and public scrutiny and reimbursement policies imposed by third-party payers, including governments, private insurance plans and managed care providers and may be affected by regulatory, clinical and guideline developments and domestic and international trends toward managed care and healthcare cost containment. Furthermore, our research, testing, pricing, marketing and other operations are subject to extensive regulation by domestic and foreign government regulatory authorities. We or others could identify safety, side effects or manufacturing problems with our products, including our devices, after they are on the market. Our business may be impacted by government investigations, litigation and product liability claims. In addition, our business may be impacted by the adoption of new tax legislation or exposure to additional tax liabilities. If we fail to meet the compliance obligations in the corporate integrity agreement between us and the U.S. government, we could become subject to significant sanctions. Further, while we routinely obtain patents for our products and technology, the protection offered by our patents and patent applications may be challenged, invalidated or circumvented by our competitors, or we may fail to prevail in present and future intellectual property litigation. We perform a substantial amount of our commercial manufacturing activities at a few key facilities, including in Puerto Rico , and also depend on third parties for a portion of our manufacturing activities, and limits on supply may constrain sales of certain of our current products and product candidate development. An outbreak of disease or similar public health threat, such as COVID-19, and the public and governmental effort to mitigate against the spread of such disease, could have a significant adverse effect on the supply of materials for our manufacturing activities, the distribution of our products, the commercialization of our product candidates, and our clinical trial operations, and any such events may have a material adverse effect on our product development, product sales, business and results of operations. We rely on collaborations with third parties for the development of some of our product candidates and for the commercialization and sales of some of our commercial products. In addition, we compete with other companies with respect to many of our marketed products as well as for the discovery and development of new products. Discovery or identification of new product candidates or development of new indications for existing products cannot be guaranteed and movement from concept to product is uncertain; consequently, there can be no guarantee that any particular product candidate or development of a new indication for an existing product will be successful and become a commercial product. Further, some raw materials, medical devices and component parts for our products are supplied by sole third-party suppliers. Certain of our distributors, customers and payers have substantial purchasing leverage in their dealings with us. The discovery of significant problems with a product similar to one of our products that implicate an entire class of products could have a material adverse effect on sales of the affected products and on our business and results of operations. Our efforts to collaborate with or acquire other companies, products or technology, and to integrate the operations of companies or to support the products or technology we have acquired, may not be successful. There can be no guarantee that we will be able to realize any of the strategic benefits, synergies or opportunities arising from the Horizon acquisition, and such benefits, synergies or opportunities may take longer to realize than expected. We may not be able to successfully integrate Horizon, and such integration may take longer, be more difficult or cost more than expected. A breakdown, cyberattack or information security breach of our information technology systems could compromise the confidentiality, integrity and availability of our systems and our data. Our stock price is volatile and may be affected by a number of events. Our business and operations may be negatively affected by the failure, or perceived failure, of achieving our environmental, social and governance objectives. The effects of global climate change and related natural disasters could negatively affect our business and operations. Global economic conditions may magnify certain risks that affect our business. Our business performance could affect or limit the ability of our Board of Directors to declare a dividend or our ability to pay a dividend or repurchase our common stock. We may not be able to access the capital and credit markets on terms that are favorable to us, or at all. CONTACT: Amgen, Thousand Oaks Elissa Snook , 609-251-1407 (media) Justin Claeys , 805-313-9775 (investors) View original content to download multimedia: https://www.prnewswire.com/news-releases/amgen-to-present-at-citis-2024-global-healthcare-conference-302319891.html SOURCE Amgen
